Abstract Library

#4669 Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial

Introduction: Patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) have limited therapeutic options.

Conference:

Presenting Author:

Authors: Capdevila J, Amthauer H, Ansquer C, Deshayes E, Garcia-Carbonero R,

Keywords: radiopharmaceutical therapy, neuroendocrine tumour, [177Lu]Lu-edotreotide, progression-free survival, gastroenteropancreatic,

#4533 Receptor radionuclide therapy with 177Lu-DOTATOC (177Luedotreotide or 177Lu-octreotide) in SSTR positive patients: A multicentre, prospective, phase II trial

Introduction: For advanced G1-G2 GEP-NET patients, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE can be recommended. However, there are several SSTR-positive tumours for which PRRT has previously shown efficacy that are not currently covered by the indications for 177Lu-DOTATATE in Italy and, therefore, cannot benefit from it. Less used and studied is the 177Lu-DOTATOC. This is a radiopeptide with excellent safety and efficacy profile in PRRT and certainly not lower than 177Lu-DOTATATE.

Conference:

Presenting Author: Sansovini M

Authors: Sansovini M, Nicolini S, Grassi I, Marini I, Matteucci F,

Keywords: Lu-dotatoc, Radiopharaceutical Therapy Factory, SSTR positive tumour,

#4132 ACTION-1: A randomised phase Ib/3 trial of RYZ101 compared with standard of care in somatostatin receptor positive, well-differentiated gastroenteropancreatic neuroendocrine tumors with progression following 177Lu somatostatin analogue therapy

Introduction: Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are characterized by high-density expression of somatostatin receptors (SSTRs). RYZ101 (225Ac-DOTATATE) is a highly potent alpha-emitting radiopharmaceutical therapy (RPT) being developed for SSTR+ solid tumors. ACTION-1 is a 2-part, global, randomized, controlled, open-label, Phase 1b/3 trial of RYZ101. Part 1 (Phase 1b), an uncontrolled dose de-escalation study, is complete with no dose-limiting toxicities.

Conference:

Presenting Author: Singh S

Authors: Singh S, Tesselaar M, Strosberg J, Jacene H, Halperin D,

Keywords: RYZ101, Gastroenteropancreatic neuroendocrine tumor, Somatostatin receptor, Radiopharmaceutical therapy,

#3964 Genomic profiling in the randomised controlled phase III COMPOSE trial of Lu-177 edotreotide for well-differentiated aggressive grade 2/3 gastroenteropancreatic-neuroendocrine tumors

Introduction: Targeted radiopharmaceutical therapy (RPT) has demonstrated potential in treatment of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). However, RPT exhibits variable outcomes and lacks tools to predict individual efficacy. To address the latter, a genomic profiling analysis was included in the randomised, controlled, open-label, phase III COMPOSE trial of Lu-177 edotreotide vs. best standard of care (CAPTEM, FOLFOX or everolimus) in patients with well differentiated, aggressive, G2/G3 somatostatin receptor-positive GEP-NETs.

Conference:

Presenting Author:

Authors: Srirajaskanthan R, Capdevila J, Halfdanarson T, Halperin D, Herrmann K,

Keywords: radiopharmaceutical therapy, genomic, Lu-177 edotreotide, gastroenteropancreatic, tumor, neuroendocrine,